^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDH6-targeted antibody-drug conjugate

    Related drugs:
    1m
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Merck Sharp & Dohme LLC | N=78 --> 280
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)
    2ms
    CUSP06-1001: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=263, Recruiting, OnCusp Therapeutics, Inc. | N=180 --> 263
    Enrollment change • First-in-human
    |
    CUSP06
    3ms
    CUSP06, a Novel CDH6-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Multiple CDH6-Expressing Human Cancer Models. (PubMed, Pharmaceutics)
    CUSP06 demonstrated a favorable safety profile in GLP-compliant toxicology studies in Sprague Dawley rats and cynomolgus monkeys. The preclinical data highlighted the therapeutic potential of CUSP06 in multiple CDH6-positive human cancers.
    Preclinical • Journal
    |
    CDH6 (Cadherin 6)
    |
    CUSP06
    3ms
    SIM0505-101: A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=414, Recruiting, NextCure, Inc. | N=172 --> 414
    Enrollment change
    4ms
    DS6000-A-U101: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors (clinicaltrials.gov)
    P1, N=179, Active, not recruiting, Daiichi Sankyo | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    raludotatug deruxtecan (DS-6000)
    5ms
    A Study of QLS5133 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=212, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial
    5ms
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=710, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    6ms
    REJOICE-GI01: A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (clinicaltrials.gov)
    P2, N=160, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2029 --> Jan 2029
    Trial completion date
    |
    raludotatug deruxtecan (DS-6000)
    8ms
    REJOICE-GI01: A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (clinicaltrials.gov)
    P2, N=160, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    raludotatug deruxtecan (DS-6000)
    8ms
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=78, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • raludotatug deruxtecan (DS-6000)
    9ms
    SIM0505-101: A Phase I Study of SIM0505 in Participants with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=172, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    9ms
    A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) (clinicaltrials.gov)
    P2, N=200, Recruiting, Daiichi Sankyo | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    raludotatug deruxtecan (DS-6000)